---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-23-000090"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:44:52.051173+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics presents new leptin analysis from Target-HTN trial of lorundrostat

## Summary
- Elevated BMI (>30 kg/m²) predicted enhanced systolic BP reduction: placebo-adjusted drops of 16.7 mmHg (50 mg) and 12.3 mmHg (100 mg).
- New analysis shows increased serum leptin correlates with higher BMI, suggesting leptin as a biomarker for responsive patients.
- Target-HTN results support transition to late-stage development; Advance-HTN pivotal trial enrolling, Launch-HTN expected H2 2023.
- Data presented at AHA Scientific Sessions 2023 in Philadelphia.

## SEC filing metadata
- accession: 0001933414-23-000090
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000090/0001933414-23-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000090/mlys-20231111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-23-000090
- JSON: https://secwatch.observer/filing/0001933414-23-000090.json
- Plain text: https://secwatch.observer/filing/0001933414-23-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.